logo
Bread Recall After ‘Glass Fragments Found' Affects 6 States, FDA Says

Bread Recall After ‘Glass Fragments Found' Affects 6 States, FDA Says

Forbes03-05-2025

There is now a bread recall due to the presence of glass fragments being found on the top of the ... More bread, according to the U.S. Food and Drug Administration. (Photo: Getty)
You could call this a glass act. There is now a bread recall due to the presence of glass fragments being found on the top of the bread, according to the U.S. Food and Drug Administration. Upper Crust Crest Hill Bakery is voluntarily recalling over 800 cases of its bread.
That's a lot of bread. Actually, that's three lots of bread. Specifically, it's Lot #90 of its Ancient Grains Hoagie Rolls involving 89 cases, Lot #90 of its Multigrain Sourdough bread involving 699 cases, and Lout #92 of its Whole Grain Multigrain bread involving 30 cases. The bread affected by the recall was originally sold frozen in paper cartons.
If you've bought bread recently, don't loaf around and delay checking your package, the package that the bread came in, that is. If you find the packaging code CP45 on the four ounce container of the Upper Crust Bakery Ancient Grains Hoagie Roll or the packaging code CP12 on the 18 ounce container of the Multigrain Sourdough or the 20 ounce container of the Whole Grain Multigrain varieties, stop eating that peanut butter an hot dog sandwich or whatever else may be using that bread. Instead, throw it away or return it for a refund.
The recall initiated on April 12 should affect six states, Pennsylvania, California, Connecticut, Maryland, Delaware and Ohio. Upper Crust Crest Hill Bakery itself is located in Maryland. But even if you are not in one of those states, you may want to check your bread. After all, bread can cross state lines.
The FDA recall notice did not specify the size of the glass fragments, how much glass was found and specifically how many bread packages have actually had glass fragments to date. When some type of contamination is found in a food product, often the manufacturer will recall the entire lot that the product was in as a precautionary measure.
Naturally, it's not a good idea to eat any glass. There are reasons why people don't routinely munch on stained glass windows. The damage that glass fragments can do to your gastrointestinal tract depends on their sharpness, shape and size. The sharper they are the more likely they are to cut through different parts of your GI tract such as your mouth, throat, esophagus, stomach and intestines. Such cuts can lead to bleeding, damage and infections. Larger glass fragments could lead to obstructions.
However, if the glass fragments are small and dull enough, they could pass through your GI tract within days without incident. If you suspect that you ingested some glass fragments, its a good idea to contact your doctor and be on the lookout for any symptoms. Symptoms may include pain in the chest or abdomen, bloating, fever, blood in the stool or coughing up blood. Describe as best you can the glass fragments as there is a difference between ingesting very small grainy fragments versus a glass tumbler versus an entire car window pane. That can help your doctor decide how to handle your situation and your risk of getting cut on the inside.
Speaking of cuts. It's not clear how the recent (and perhaps ongoing) cuts of FDA staff and resources may be affecting inspections and food safety oversight. During the past couple of months, the FDA doesn't seem to be issuing as many full press releases about food recalls as it has done in the past. Regardless, you probably don't want to hear of something like a bread recall after you've eaten bread that's been contaminated. So, try to inspect any food that you are about to eat before it goes down you pie hole. Look for any unusual appearance or any foreign substances. In other words, check your bread slice on its outside before you get sliced on the inside.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SeaStar's QUELIMMUNE Can Cut Pediatric Sepsis Deaths In Half
SeaStar's QUELIMMUNE Can Cut Pediatric Sepsis Deaths In Half

Associated Press

time2 days ago

  • Associated Press

SeaStar's QUELIMMUNE Can Cut Pediatric Sepsis Deaths In Half

By Meg Flippin Benzinga DETROIT, MICHIGAN - June 27, 2025 ( NEWMEDIAWIRE ) - SeaStar Medical Holding Corp. (NASDAQ: ICU), the commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, has made a lot of inroads on that front with QUELIMMUNE. A humanitarian medical device, QUELIMMUNE treats pediatric patients with acute kidney injury or AKI due to sepsis or a septic condition. The QUELIMMUNE therapy received U.S. Food and Drug Administration approval in 2024 after clinical trials showed it could cut mortality in half from 50% to 25%. 'QUELIMMUNE is designed to target the innate immune response. When patients get very sick, it becomes very dysregulated and cells go haywire and trigger something called the cytokine storm,' said Dr. Kevin Chung, MD, Chief Medical Officer at SeaStar Medical. 'The QUELIMMUNE device is designed specifically to target the cytokine storm at the source of the storm and it is associated with really good outcomes, especially in the pediatric population where mortality was cut in half from 50% to 25%.' From The Golf Course To The ICU That was the case for Kurt, a young student and avid golfer who has won multiple golf awards even though he underwent two open-heart surgeries before his sixth birthday. Knowing at an early age that he couldn't compete in the sports other kids were playing, Kurt picked up golf and never looked back. But over the years, Kurt faced doctor visits and surgeries, culminating in a near-death experience. At the time, Kurt was being treated at Cincinnati Children's Hospital Medical Center, where Dr. Stuart L. Goldstein, MD, the lead researcher for QUELIMMUNE's two trials that led to the device's FDA approval, worked. Kurt went in for a planned surgery to address an artificial replacement from his pulmonary to aortic valve, but had to be opened up again two days later as a result of blood leaking from his heart at the site of surgery. Kurt was put on a ventilator and went into multiple-organ failure, caught hospital pneumonia, and ultimately endured a 12-day coma. He developed AKI and respiratory failure, and doctors prepared to put him on ECMO (Extracorporeal Membrane Oxygenation), a more invasive type of support. But Dr. Goldstein spoke with the on-staff cardiologist and Kurt's family and suggested that the QUELLIMUNE therapy would be helpful for him. 'Kurt just started to turn around within 24 to 48 hours and did not require ECMO. Kurt left the ICU within two to three weeks and resumed going back to school and golfing,' says Dr. Goldstein. 'It was quite dramatic and is emblematic of when we see this work, which is far more often than not, patients turn around really really quickly when you wouldn't expect them to.' A Christmas Miracle For Kurt's father, David, the QUELIMMUNE therapy was a last-ditch effort to save his son, who had been languishing in the ICU for eleven days. Every night, the doctors would offer up different therapies and treatment ideas to stop his son's organs from failing and as luck would have it, one evening David and his nephew, who is also a doctor, ran into Dr. Goldstein outside of his son's room. Dr. Goldstein said he thought the QUELIMMUNE therapy could help with the inflammation and the family decided, given the apparently bleak prognosis, to give it a try, recalls David. From day two on, the inflammatory markers improved and continued to get a lot better. 'The inflammatory markers improved every day,' says David. His son was woken from the coma on day six of treatment, December 24. 'It was a Christmas miracle. He was awake and his numbers were improving,' his father said. Kurt had a tough recovery ahead of him when he woke up. He entered the hospital weighing 150 pounds and left at about 120 pounds. But by the beginning of March, he had regained his strength and energy and was golfing again. That is one of the other aspects of the QUELIMMUNE therapy that astonishes Dr. Goldstein, and makes him so optimistic that the device can treat other children with AKI. Typically 10% to 30% of pediatric patients who survive an AKI episode require chronic dialysis, but Kurt didn't. 'It is nothing I've seen before in clinical medicine in the last quarter century,' said Dr. Goldstein. Featured image fromShutterstock This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. This content was originallypublished on further disclosureshere.

'Essence' Celebrates Susan L. Taylor In 55th Anniversary Issue
'Essence' Celebrates Susan L. Taylor In 55th Anniversary Issue

Black America Web

time2 days ago

  • Black America Web

'Essence' Celebrates Susan L. Taylor In 55th Anniversary Issue

Source: Johnny Nunez / Getty For its 55th anniversary, Essence magazine is paying tribute to one of its most legendary figures, iconic journalist, mental health advocate, and former Editor-in-Chief, Susan L. Taylor. At 79, Taylor is still dropping gems, sharing timeless wisdom about faith, purpose, and the importance of community healing. Though it's been 17 years since Taylor stepped down from her historic role as Essence's Editor-in-Chief and Beauty Editor, her mission to uplift and empower Black communities hasn't wavered and has not been forgotten. In fact, it's only grown. During an interview published June 25 and conducted by her longtime mentee, award-winning author and journalist asha bandele, Taylor reflected on the divine power of service, and how it continues to guide her writing and advocacy. Under her legendary role as Editor-in-Chief, Taylor spent years penning the beloved monthly column 'In the Spirit,' where she shared powerful reflections on spirituality, personal growth, and inner healing, sharing all the ups and downs of her life and lessons readers gravitated to. Essence Celebrates Susan L. Taylor 'I just said, be yourself. Write about what you care about most and what you're most interested in investigating. And it was spirituality,' the icon told bandele in an interview for the exclusive feature. The Harlemite originally launched Essence CARES in the aftermath of Hurricane Katrina in 2005, calling on the collective compassion of the Black community to support displaced and traumatized children in New Orleans. That initiative evolved into the National CARES Mentoring Movement, a nationwide organization focused on healing and transforming the lives of Black youth through mentoring and holistic development. Today, National CARES continues to recruit and mobilize Black mentors across the country, connecting them with local youth organizations. Its programs focus not just on academic success, but on the emotional and mental well-being of both children and the adults who care for them. As Taylor shared in her powerful conversation with bandele, it's the spirit of service—and a deep commitment to mental health and spiritual wellness—that fuels her work to this day. 'I don't name it courage. It's service. And if you love the community and you're devoted to serving the community, you do and deliver what the community needs.' Taylor saw Essence as not only a tool to center Black stories and perspectives but as an opportunity to inform a larger audience about the issues impacting our community. Since leaving Essence, she's poured her heart and soul into highlighting the mental health crisis impacting Black youth. According to the Substance Abuse and Mental Health Services Administration (SAMHSA), suicide, a sequela of untreated depression, rose sharply among Black teens from 8.2% in 2018 to 11.2% in 2021, reflecting an alarming 36.6% increase. In 2021, suicide became the third leading cause of death among Black youth. Sadly, a 2024 study indicated that Black teens experienced a higher prevalence of dysthymic disorder, also known as persistent depressive disorder, with rates peaking during the pandemic. Researchers believe this surge may have been triggered by the traumatic loss of life, poverty, violence, social isolation, and systemic disparities that worsened during this period. 'Many of our finest organizations, including ones closest to us, do transformational work by changing policies on voting, criminal justice, and healthcare. We need that work desperately. But still, there is no lobbying at those levels to protect Black children and lift them out of poverty,' Taylor told bandele. 'We knew then what we know now: Policies alone do not change systems, as evidenced by the 1954 Supreme Court's Brown v. Board of Education decision declaring racial segregation in public education illegal. Despite that unanimous decision, 71 years later, our schools are even more segregated. No one is coming to save our babies—or us. This is our work to do!' Taylor isn't just talking the talk—she's walking the walk. Under her leadership, the National CARES Mentoring Movement has become a vital resource for Black youth and their families across the country. One of the organization's standout initiatives is In Wellness Mentoring Circles, where licensed psychologists, social workers, and trained community mentors guide young people through dynamic, culturally grounded, and trauma-informed programming. These interactive sessions help build social-emotional skills, self-confidence, and a sense of personal power, all within a judgment-free environment rooted in love and care. For parents, National CARES offers the University for Parents (U4P), a healing-centered workforce readiness program designed to help caregivers overcome both systemic and self-imposed barriers to success. Through partnerships with local organizations, U4P provides wraparound services that support not just parents but their entire families, promoting stability, empowerment, and long-term growth. Reflecting on her incredible life's work, Taylor thanked God for allowing her to walk in her purpose. 'God is alive in you, take pause and listen,' she added during her beautiful heart-to-heart with bandele. DON'T MISS… How The Fear Of Dying From Blood Cancer Helped Me Live Former Essence Editor-in-Chief Details Why She Left Time Inc. 'Essence' Celebrates Susan L. Taylor In 55th Anniversary Issue, Honoring Her Legacy Of Leadership was originally published on

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA
Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

Business Wire

time2 days ago

  • Business Wire

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the recent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The MAA includes response-based analyses in narsoplimab-treated TA-TMA patients as well as analyses comparing overall survival between narsoplimab-treated patients and a well-matched external control group. Collectively, the results demonstrate a 61% response rate and, compared to the matched external control, a three-fold improvement in overall survival. The submission also includes outcomes in over 130 TA-TMA patients treated with narsoplimab under Omeros' expanded access program. Narsoplimab has been granted orphan drug designation by the EMA for treatment in hematopoietic stem cell transplant, enabling review of the MAA through the centralized procedure. This allows for a single marketing authorization to cover all EU member states and the European Economic Area countries of Iceland, Liechtenstein and Norway. The review procedure begins in mid-July and will follow a standard review timeline. The Committee for Medicinal Products for Human Use (CHMP) will conduct the scientific assessment and will issue an opinion at the end of the review. This opinion is typically adopted by the European Commission, with a final decision expected in mid-2026. The MAA submission follows the acceptance for review by the U.S. Food and Drug Administration (FDA) of the resubmission of the Biologics License Application (BLA) for narsoplimab for the treatment of TA-TMA. The resubmission was assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 25, 2025. About Narsoplimab Narsoplimab, also known as 'OMS721,' is an investigational fully human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), a novel pro-inflammatory protein target and the effector enzyme of the lectin pathway of complement. Importantly, inhibition of MASP-2 has been demonstrated to leave intact the antibody-dependent classical complement activation pathway, which is a critical component of the acquired immune response to infection. A biologics license application (BLA) for use of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) is under review by the U.S. Food and Drug Administration (FDA) and Omeros has submitted the corresponding European MAA. FDA has granted narsoplimab breakthrough therapy and orphan drug designations for TA-TMA and orphan drug status for the prevention (inhibition) of complement-mediated thrombotic microangiopathies. The European Medicines Agency has granted orphan drug designation to narsoplimab for treatment in hematopoietic stem-cell transplant. About Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) Hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) is a significant and often lethal complication of stem cell transplantation. This condition is a systemic, multifactorial disorder caused by endothelial cell damage induced by conditioning regimens, immunosuppressant therapies, infection, graft-versus-host disease, and other factors associated with stem cell transplantation. Endothelial damage, which activates the lectin pathway of complement, plays a central role in the development of TA-TMA. The condition occurs in both autologous and allogeneic transplants but is more common in the allogeneic population. In the United States and Europe, approximately 30,000 allogeneic transplants are performed annually. Recent reports in both adult and pediatric allogeneic stem cell transplant populations have found an approximately 40-percent incidence of TA-TMA, and high-risk features may be present in up to 80 percent of these patients. In severe cases of TA-TMA, mortality can exceed 90 percent and, even in those who survive, long-term renal sequalae (e.g., dialysis) are common. There is no approved therapy or standard of care for TA-TMA. About Omeros Corporation Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing first-in-class small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases and cancers, as well as addictive and compulsive disorders. Omeros' lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application under review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Omeros' long-acting MASP-2 inhibitor OMS1029 has successfully completed Phase 1 single- and multiple-ascending dose clinical studies. OMS906, Omeros' inhibitor of MASP-3, the key activator of the alternative pathway of complement, is in clinical development for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Funded by the National Institute on Drug Abuse, Omeros' lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorder. Omeros also is advancing a broad portfolio of novel cellular and molecular immuno-oncology programs. For more information about Omeros and its programs, visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the 'safe harbor' created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'goal,' 'intend,' 'likely,' 'look forward to,' 'may,' 'objective,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'slate,' 'target,' 'will,' 'would' and similar expressions and variations thereof. Forward-looking statements, including statements regarding the anticipated review process and timing of FDA action on the resubmitted BLA for narsoplimab in the United States, the anticipated review process and timing of EMA action on the MAA submission, the prospects for obtaining FDA or EMA approval of narsoplimab in any indication, and expectations regarding the sufficiency and availability of our capital resources to fund current and planned operations, including the potential commercialization of narsoplimab if it is approved by FDA or the EMA, are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, unfavorable or unexpected regulatory conclusions or interpretations related to the clinical data, external registry data, statistical analyses or other information and data included in the narsoplimab BLA or narsoplimab MAA, inability to respond satisfactorily to information requests during regulatory review of the narsoplimab BLA or MAA, potential differences between the diagnostic criteria used in our pivotal trial and in the external registry, and whether FDA and the EMA determine the registry used in our statistical analysis is sufficiently representative of TA-TMA patients, unanticipated or unexpected outcomes or requirements of regulatory processes in relevant jurisdictions, our financial condition and results of operations, including our ability to raise additional capital for our operations on favorable terms or at all, regulatory processes and oversight, challenges associated with manufacture or supply of our products to support clinical trials, regulatory inspections and/or commercial sale following any marketing approval, changes in reimbursement and payment policies by government and commercial payers or the application of such policies, intellectual property claims, competitive developments, litigation, and the risks, uncertainties and other factors described under the heading 'Risk Factors' in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2025 and in subsequent reports filed with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store